Deal Watch: Bristol, Pfizer Lead Off J.P. Morgan Week With Two Deals Apiece
Despite no mega-deals (yet), the J.P. Morgan Healthcare Conference’s first day brings the usual flurry of deals, including a pair of tie-ups each for Bristol and Pfizer. BioNTech moves into cancer with Crescendo.
You may also be interested in...
Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round.
Deal Snapshot: In its third biopharma collaboration this year, Ginkgo will apply its genetic engineering technologies to using Bacteroides for stable delivery of microbiome medicines.
Gene editing is positioning itself as the latest evolution of genetic therapies and is due for an inflection point in 2022 as a number of milestones will be reached.